Transmembrane amyloid-related proteins in CSF as potential biomarkers for Alzheimer's disease

Frontiers in Neurology

Volumn 6, Issue JUN, 2015, Pages

  Lopez Font, Inmaculada ^a,b   Cuchillo Ibañez, Inmaculada ^a,b   Sogorb Esteve, Aitana ^a,b   García Ayllón, María Salud ^a,b,c   Sáez Valero, Javier ^a,b  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

Alzheimer's disease; BACE1; Cerebrospinal fluid; Presenilin 1; Soluble amyloid precursor protein; TACE

Indexed keywords

ADAM10 ENDOPEPTIDASE; ADAM8; ADAM9; ALPHA SECRETASE; AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; ANTERIOR PHARYNX DEFECTIVE 1 PROTEIN; BETA SECRETASE 1; BIOLOGICAL MARKER; GAMMA SECRETASE; MEMBRANE PROTEIN; METALLOPROTEINASE; NICASTRIN; PRESENILIN; PRESENILIN 1; PRESENILIN ENHANCER 2; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; ENZYME ACTIVITY; HUMAN; HYDROPHOBICITY; MOLECULAR PATHOLOGY; NEUROPATHOLOGY; OLIGOMERIZATION; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN CLEAVAGE; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; SHORT SURVEY;

EID: 84936937876     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2015.00125     Document Type: Short Survey

References (64)

1. Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement (2015) 11:58-69. doi: 10.1016/j.jalz.2014.02.004
2. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6:131-44. doi:10.1038/nrneurol.2010.4
3. Rosen C, Hansson O, Blennow K, Zetterberg H. Fluid biomarkers in Alzheimer's disease - current concepts. Mol Neurodegener (2013) 8:20. doi:10.1186/1750-1326-8-20
4. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 297:353-6. doi:10.1126/science.1072994
5. Steiner H, Fluhrer R, Haass C. Intramembrane proteolysis by gamma-secretase. J Biol Chem (2008) 283:29627-31. doi:10.1074/jbc.R800010200
6. Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem (2008) 283:29615-9. doi:10.1074/jbc.R800019200
7. Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, et al. A novel pathway for amyloid precursor protein processing. Neurobiol Aging (2011) 32:1090-8. doi:10.1016/j.neurobiolaging.2009.06.002
8. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 9:119-28. doi:10.1016/S1474-4422(09)70299-6
9. Wolfe MS. γ-Secretase as a target for Alzheimer's disease. Adv Pharmacol (2012) 64:127-53. doi:10.1016/B978-0-12-394816-8.00004-0
10. Yan R, Vassar R. Targeting the β secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol (2014) 13:319-29. doi:10.1016/S1474-4422(13)70276-X
11. Palmert MR, Podlisny MB, Witker DS, Oltersdorf T, Younkin LH, Selkoe DJ, et al. The beta-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid. Proc Natl Acad Sci U S A (1989) 86:6338-42. doi:10.1073/pnas.86.16.6338
12. Ghiso J, Tagliavini F, Timmers WF, Frangione B. Alzheimer's disease amyloid precursor protein is present in senile plaques and cerebrospinal fluid: immunohistochemical and biochemical characterization. Biochem Biophys Res Commun (1989) 163:430-7. doi:10.1016/0006-291X(89)92154-2
13. Perneczky R, Alexopoulos P, Kurz A. Soluble amyloid precursor proteins and secretases as Alzheimer's disease biomarkers. Trends Mol Med (2014) 20:8-15. doi:10.1016/j.molmed.2013.10.001
14. Efthimiopoulos S, Vassilacopoulou D, Ripellino JA, Tezapsidis N, Robakis NK. Cholinergic agonists stimulate secretion of soluble full-length amyloid precursor protein in neuroendocrine cells. Proc Natl Acad Sci U S A (1996) 93:8046-50. doi:10.1073/pnas.93.15.8046
15. Tezapsidis N, Li HC, Ripellino JA, Efthimiopoulos S, Vassilacopoulou D, Sambamurti K, et al. Release of nontransmembrane full-length Alzheimer's amyloid precursor protein from the lumenar surface of chromaffin granule membranes. Biochemistry (1998) 37:1274-82. doi:10.1021/bi9714159
16. Cuchillo-Ibañez I, Lopez-Font I, Boix-Amorós A, Brinkmalm G, Blennow K, Molinuevo JL, et al. Heteromers of amyloid precursor protein in cerebrospinal fluid. Mol Neurodegener (2015) 10:2. doi:10.1186/1750-1326-10-2
17. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, et al. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry (2010) 15:138-45. doi:10.1038/mp.2008.84
18. Gabelle A, Roche S, Gény C, Bennys K, Labauge P, Tholance Y, et al. Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid. Brain Res (2010) 21:175-83. doi:10.1016/j.brainres.2010.08.022
19. Mulugeta E, Londos E, Hansson O, Ballard C, Skogseth R, Minthon L, et al. Cerebrospinal fluid levels of sAPPα and sAPPβ in Lewy body and Alzheimer's disease: clinical and neurochemical correlates. Int J Alzheimers Dis (2011) 2011:495025. doi:10.4061/2011/495025
20. Alexopoulos P, Tsolakidou A, Roselli F, Arnold A, Grimmer T, Westerteicher C, et al. Clinical and neurobiological correlates of soluble amyloid precursor proteins in the cerebrospinal fluid. Alzheimers Dement (2012) 8:304-11. doi:10.1016/j.jalz.2011.04.009
21. Sennvik K, Fastbom J, Blomberg M, Wahlund LO, Winblad B, Benedikz E. Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett (2000) 278:169-72. doi:10.1016/S0304-3940(99)00929-5
22. Blennow K. Biomarkers in Alzheimer's disease drug development. Nat Med (2010) 16:1218-22. doi:10.1038/nm.2221
23. Karran E, Hardy J. Antiamyloid therapy for Alzheimer's disease - are we on the right road? N Engl J Med (2014) 370:377-8. doi:10.1056/NEJMe1313943
24. May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, et al. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor. J Neurosci (2011) 31:16507-16. doi:10.1523/JNEUROSCI.3647-11.2011
25. García-Ayllón MS, Campanari ML, Brinkmalm G, Rábano A, Alom J, Saura CA, et al. CSF presenilin-1 complexes are increased in Alzheimer's disease. Acta Neuropathol Commun (2013) 1:46. doi:10.1186/2051-5960-1-46
26. Tanaka S, Nakamura S, Ueda K, Kameyama M, Shiojiri S, Takahashi Y, et al. Three types of amyloid protein precursor mRNA in human brain: their differential expression in Alzheimer's disease. Biochem Biophys Res Commun (1988) 157:472-9. doi:10.1016/S0006-291X(88)80273-0
27. Dobrowolska JA, Michener MS, Wu G, Patterson BW, Chott R, Ovod V, et al. CNS amyloid-β, soluble APP-α and -β kinetics during BACE inhibition. J Neurosci (2014) 34:8336-46. doi:10.1523/JNEUROSCI.0540-14.2014
28. Vassar R, Kovacs DM, Yan R, Wong PC. The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J Neurosci (2009) 29:12787-94. doi:10.1523/JNEUROSCI.3657-09.2009
29. Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, et al. Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem (2005) 280:30797-806. doi:10.1074/jbc.M505249200
30. Haque A, Banik NL, Ray SK. New insights into the roles of endolysosomal cathepsins in the pathogenesis of Alzheimer's disease: cathepsin inhibitors as potential therapeutics. CNS Neurol Disord Drug Targets (2008) 7:270-7. doi:10.2174/187152708784936653
31. Holsinger RM, McLean CA, Collins SJ, Masters CL, Evin G. Increased beta-secretase activity in cerebrospinal fluid of Alzheimer's disease subjects. Ann Neurol (2004) 55:898-9. doi:10.1002/ana.20144
32. Decourt B, Sabbagh MN. BACE1 as a potential biomarker for Alzheimer's disease. J Alzheimers Dis (2011) 24(Suppl 2):53-9. doi:10.3233/JAD-2011-110017
33. Zhong Z, Ewers M, Teipel S, Bürger K, Wallin A, Blennow K, et al. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry (2007) 64:718-26. doi:10.1001/archpsyc.64.6.718
34. Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol (2008) 65:1102-7. doi:10.1001/archneur.65.8.1102
35. Benjannet S, Elagoz A, Wickham L, Mamarbachi M, Munzer JS, Basak A, et al. Post-translational processing of beta-secretase (beta-amyloid-converting enzyme) and its ectodomain shedding. The pro- and transmembrane/cytosolic domains affect its cellular activity and amyloid-beta production. J Biol Chem (2001) 276:10879-87. doi:10.1074/jbc.M009899200
36. Hussain I, Hawkins J, Shikotra A, Riddell DR, Faller A, Dingwall C. Characterization of the ectodomain shedding of the beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1). J Biol Chem (2003) 278:36264-8. doi:10.1074/jbc.M304186200
37. Verheijen JH, Huisman LG, Neumann U, Paganetti P, Hack CE, Bouwman F. Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. Clin Chem (2006) 52:1168-74. doi:10.1373/clinchem.2006.066720
38. Wu G, Sankaranarayanan S, Tugusheva K, Kahana J, Seabrook G, Shi XP, et al. Decrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer's subjects. Clin Biochem (2008) 41:986-96. doi:10.1016/j.clinbiochem.2008.04.022
39. Wu G, Sankaranarayanan S, Wong J, Tugusheva K, Michener MS, Shi X, et al. Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease. J Neurosci Res (2012) 90:2247-58. doi:10.1002/jnr.23122
40. Murayama KS, Kametani F, Araki W. Extracellular release of BACE1 holoproteins from human neuronal cells. Biochem Biophys Res Commun (2005) 338:800-7. doi:10.1016/j.bbrc.2005.10.015
41. Schmechel A, Strauss M, Schlicksupp A, Pipkorn R, Haass C, Bayer TA, et al. Human BACE forms dimers and colocalizes with APP. J Biol Chem (2004) 279:39710-7. doi:10.1074/jbc.M402785200
42. Westmeyer GG, Willem M, Lichtenthaler SF, Lurman G, Multhaup G, Assfalg-Machleidt I, et al. Dimerization of beta-site beta-amyloid precursor protein-cleaving enzyme. J Biol Chem (2004) 279:53205-12. doi:10.1074/jbc.M410378200
43. Barão S, Zhou L, Adamczuk K, Vanhoutvin T, van Leuven F, Demedts D, et al. BACE1 levels correlate with phospho-tau levels in human cerebrospinal fluid. Curr Alzheimer Res (2013) 10:671-8. doi:10.2174/15672050113109990138
44. Vingtdeux V, Marambaud P. Identification and biology of α-secretase. J Neurochem (2012) 120:34-45. doi:10.1111/j.1471-4159.2011.07477.x
45. Naus S, Reipschläger S, Wildeboer D, Lichtenthaler SF, Mitterreiter S, Guan Z, et al. Identification of candidate substrates for ectodomain shedding by the metalloprotease-disintegrin ADAM8. Biol Chem (2006) 387:337-46. doi:10.1515/BC.2006.045
46. Jorissen E, Prox J, Bernreuther C, Weber S, Schwanbeck R, Serneels L, et al. The disintegrin/metalloproteinase ADAM10 is essential for the establishment of the brain cortex. J Neurosci (2010) 30:4833-44. doi:10.1523/JNEUROSCI.5221-09.2010
47. Kuhn PH, Wang H, Dislich B, Colombo A, Zeitschel U, Ellwart JW, et al. ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J (2010) 29:3020-32. doi:10.1038/emboj.2010.167
48. Colciaghi F, Borroni B, Pastorino L, Marcello E, Zimmermann M, Cattabeni F, et al. α-Secretase ADAM10 as well as αAPPs is reduced in platelets and CSF of Alzheimer disease patients. Mol Med (2002) 8:67-74.
49. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med (2008) 29:258-89. doi:10.1016/j.mam.2008.08.001
50. Jiang H, Hampel H, Prvulovic D, Wallin A, Blennow K, Li R, et al. Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease. Mol Neurodegener (2011) 6:69. doi:10.1186/1750-1326-6-69
51. Bai L, Song N, Yu J, Tan L, Shen Y, Xie J, et al. Elevated plasma levels of soluble TNFRs and TACE activity in Alzheimer's disease patients of Northern Han Chinese descent. Curr Alzheimer Res (2013) 10:57-62. doi:10.2174/1567205011310010008
52. Sun Q, Hampel H, Blennow K, Lista S, Levey A, Tang B, et al. Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer's disease. J Alzheimers Dis (2014) 41:877-86. doi:10.3233/JAD-140177
53. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, et al. An essential role for ectodomain shedding in mammalian development. Science (1998) 282:1281-4. doi:10.1126/science.282.5392.1281
54. Stoeck A, Keller S, Riedle S, Sanderson MP, Runz S, Le Naour F, et al. A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. Biochem J (2006) 393:609-18. doi:10.1042/BJ20051013
55. Kaether C, Haass C, Steiner H. Assembly, trafficking and function of gamma-secretase. Neurodegener Dis (2006) 3:275-83. doi:10.1159/000095267
56. Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, Kim G, et al. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron (1996) 17:181-90. doi:10.1016/S0896-6273(00)80291-3
57. Laudon H, Hansson EM, Melén K, Bergman A, Farmery MR, Winblad B, et al. A nine-transmembrane domain topology for presenilin 1. J Biol Chem (2005) 280:35352-60. doi:10.1074/jbc.M507217200
58. Wakabayashi T, De Strooper B. Presenilins: members of the gamma-secretase quartets, but part-time soloists too. Physiology (Bethesda) (2008) 23:194-204. doi:10.1152/physiol.00009.2008
59. Benussi L, Alberici A, Mayhaus M, Langer U, Ghidoni R, Mazzoli F, et al. Detection of the presenilin 1 COOH-terminal fragment in the extracellular compartment: a release enhanced by apoptosis. Exp Cell Res (2001) 269:256-65. doi:10.1006/excr.2001.5329
60. De Strooper B, Beullens M, Contreras B, Levesque L, Craessaerts K, Cordell B, et al. Phosphorylation, subcellular localization, and membrane orientation of the Alzheimer's disease-associated presenilins. J Biol Chem (1997) 272:3590-8. doi:10.1074/jbc.272.6.3590
61. Oresković D, Klarica M. The formation of cerebrospinal fluid: nearly a hundred years of interpretations and misinterpretations. Brain Res Rev (2010) 64:241-62. doi:10.1016/j.brainresrev.2010.04.006
62. Damkier HH, Brown PD, Praetorius J. Cerebrospinal fluid secretion by the choroid plexus. Physiol Rev (2013) 93:1847-92. doi:10.1152/physrev.00004.2013
63. Lehtinen MK, Bjornsson CS, Dymecki SM, Gilbertson RJ, Holtzman DM, Monuki ES. The choroid plexus and cerebrospinal fluid: emerging roles in development, disease, and therapy. J Neurosci (2013) 33:17553-9. doi:10.1523/JNEUROSCI.3258-13.2013
64. David MA, Tayebi M. Detection of protein aggregates in brain and cerebrospinal fluid derived from multiple sclerosis patients. Front Neurol (2014) 5:251. doi:10.3389/fneur.2014.00251